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Coronary artery disease (CAD) is prevalent in candidatesfor lung volume reduction surgery (LVRS),1 and signif-icant valve dysfunction may also coexist with severeemphysema. The National Emphysema Treatment Trial
(NETT) excludes patients with a variety of cardiovascular risk fac-
tors from undergoing LVRS,2 as do many surgeons who perform
the procedure outside of the trial. Few have performed LVRS in
those patients with severe CAD that cannot be managed percuta-
neously. Thus, although the literature on combining cardiac proce-
dures and pulmonary resections for cancer is extensive, we have
identified only 4 published cases3-5 from 3 different groups using
diverse operative strategies combining cardiac procedures and
LVRS. We report our series of 4 combined, simultaneous car-
diac/LVRS procedures to aid in determining whether this is an
appropriate approach in selected patients and, if so, to help select
the ideal operative strategy.
Patients and Results 
Four patients underwent combined cardiac/bilateral LVRS proce-
dures via median sternotomy between May 1997 and May 2000.
These 4 patients represent all those in whom there was a preoper-
ative plan to perform a combined procedure. That is, no planned
combined procedures were aborted because of intraoperative
events. Three patients had coronary artery bypass grafting (CABG)
in combination with LVRS, and 1 patient underwent aortic valve
replacement (AVR) with LVRS. Each CABG/LVRS included a left
internal thoracic artery graft; there were 1 single vessel CABG (for
left anterior descending disease spanning a large diagonal orifice
thought not amenable to angioplasty) and 2 double vessel CABGs.
A bioprosthetic valve was used for the AVR/LVRS. All patients
were excellent candidates for LVRS on the basis of hyperexpan-
sion (Table 1), disease distribution (mean upper third lung perfu-
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sion 6.1%), and the absence of pulmonary factors believed by the
surgeons to increase operative risk (eg, absence of marked PCO2
elevation or dramatically low diffusing capacity of the lung for car-
bon monoxide). Similarly, all patients had normal ejection frac-
tions, and the planned cardiac procedures were deemed relatively
straightforward. Mean age was 64.8 years.
The cardiac procedures were each performed with cardiopul-
monary bypass (CPB) before LVRS. Lung volume reduction was
performed while still on CPB in 1 patient and after heparin rever-
sal and termination of CPB in 3 patients. Mean operative time was
207 minutes. One patient was extubated in the operating room and
the others were extubated a mean of 14 hours postoperatively.
There were no major complications and 5 minor complications
including atrial fibrillation (n = 1), superficial wound infection 
(n = 1), and air leak greater than 7 days (n = 3). Mean length of
stay was 9.8 days. Three patients were discharged with Heimlich
valves; mean time to removal of all chest tubes was 11.5 days. All
patients are alive and well a mean of 22.8 months after the proce-
dure. Postoperative pulmonary function tests have been obtained in
3 patients. Postoperative improvements in pulmonary function are
similar to those reported after isolated LVRS procedures (Table 1). 
Discussion 
Untreated, significant CAD or valvular disease increases the risk
of morbidity and mortality associated with pulmonary surgery.
These increased risks are likely to be even more important after an
operation such as LVRS that severely stresses patients who begin
with marginally compensated cardiopulmonary function. Although
many candidates for LVRS have CAD that may be amenable to
correction by percutaneous intervention, some have multivessel
disease, single vessel disease not appropriate for angioplasty, or
valvular disease that requires operative repair. Options in these
patients include foregoing LVRS, performing LVRS and the car-
diac procedure under separate anesthetics, or combining the 2 pro-
cedures in a single operation, as we have done in the 4 cases report-
ed here. 
If such a simultaneous procedure can be performed with the
same morbidity, mortality, and functional outcome as the proce-
dures performed separately, then there are several reasons to favor
the simultaneous procedure. The most obvious advantages are the
improved patient convenience and the almost certainly reduced
costs associated with combining the operations. More important,
however, is the avoidance of difficulties that may be associated
with performing the operations singly. For example, a redo ster-
notomy to perform the second procedure increases risk unneces-
sarily, and even if one is performing a thoracoscopic LVRS
remotely after sternotomy, there are likely to be problems with
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adhesions and resulting air leaks. Finally, some patients who are
denied a cardiac operation because of their poor pulmonary func-
tion may, however, be candidates for a combined procedure. 
We demonstrate by the 4 cases reported herein that simultaneous
performance of LVRS and cardiac procedures using CPB can be done
safely and with improvements in pulmonary function similar to those
reported after isolated LVRS procedures. Although others have
reported performing the LVRS portion before CPB4 or while the
patient is still anticoagulated on CPB,3 we favor performing the car-
diac procedure first, with heparin reversal and discontinuation of
CPB before LVRS. This technique, which we used in 3 of our 4
patients, does not preclude creating a left internal thoracic artery
graft. Furthermore, this approach minimizes the risk of pulmonary
contusion and allows the surgeon to see the lung in the incompletely
deflated state that highlights gas-retaining target areas. 
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TABLE 1.   Preoperative and postoperative testing
FEV1 RV 6MWT (ft) O2 RA ABG
Preop 0.91 L (27%) 5.46 L (240%) 1304 1 L 7.41/43/69/27
Postop 1.14 L (35%) 3.03 L (134%) 1441 0.33 L —
% Change +55 –44 +14 –66 —
Preoperative studies include all 4 patients; postoperative studies and percent changes include 3 of the 4 patients. Postoperative studies were performed
3 to 12 months after the operations. All values are means. FEV1, Forced expiratory volume in 1 second; RV, residual volume; 6MWT, 6-minute walking test;
O2 , oxygen; RA, room air; ABG, arterial blood gases.
